메뉴 건너뛰기




Volumn 32, Issue 3, 2015, Pages 276-281

Increased risk for atypical fractures associated with bisphosphonate use

Author keywords

Osteoporosis; Prevention; Primary care; Risk assessment

Indexed keywords

ALENDRONIC ACID; BISPHOSPHONIC ACID DERIVATIVE; ETIDRONIC ACID; ZOLEDRONIC ACID; BONE DENSITY CONSERVATION AGENT;

EID: 84930810331     PISSN: 02632136     EISSN: 14602229     Source Type: Journal    
DOI: 10.1093/fampra/cmu088     Document Type: Article
Times cited : (18)

References (27)
  • 1
    • 11844251380 scopus 로고    scopus 로고
    • Rockville, MD: US Dept of Health and Human Services, Office of the Surgeon General
    • US Department of Health and Human Services. Bone Health and Osteoporosis: A Report of the Surgeon General. Rockville, MD: US Dept of Health and Human Services, Office of the Surgeon General, 2004.
    • (2004) Bone Health and Osteoporosis: A Report of the Surgeon General
  • 3
    • 79951819873 scopus 로고    scopus 로고
    • Trends in incidence of subtrochanteric fragility fractures and bisphosphonate use among the US elderly, 1996-2007
    • Wang Z, Bhattacharyya T. Trends in incidence of subtrochanteric fragility fractures and bisphosphonate use among the US elderly, 1996-2007. J Bone Miner Res 2011; 26: 553-60.
    • (2011) J Bone Miner Res , vol.26 , pp. 553-560
    • Wang, Z.1    Bhattacharyya, T.2
  • 4
    • 0004851872 scopus 로고    scopus 로고
    • Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group
    • Black DM, Cummings SR, Karpf DB et al. Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group. Lancet 1996; 348: 1535-41.
    • (1996) Lancet , vol.348 , pp. 1535-1541
    • Black, D.M.1    Cummings, S.R.2    Karpf, D.B.3
  • 5
    • 0032583492 scopus 로고    scopus 로고
    • Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial
    • Cummings SR, Black DM, Thompson DE et al. Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial. JAMA 1998; 280: 2077-82.
    • (1998) JAMA , vol.280 , pp. 2077-2082
    • Cummings, S.R.1    Black, D.M.2    Thompson, D.E.3
  • 6
    • 33845890326 scopus 로고    scopus 로고
    • Effects of continuing or stopping alendronate after 5 years of treatment: the Fracture Intervention Trial Long-term Extension (FLEX): a randomized trial
    • Black DM, Schwartz AV, Ensrud KE et al.; FLEX Research Group. Effects of continuing or stopping alendronate after 5 years of treatment: the Fracture Intervention Trial Long-term Extension (FLEX): a randomized trial. JAMA 2006; 296: 2927-38.
    • (2006) JAMA , vol.296 , pp. 2927-2938
    • Black, D.M.1    Schwartz, A.V.2    Ensrud, K.E.3
  • 7
    • 34247866550 scopus 로고    scopus 로고
    • Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis
    • Black DM, Delmas PD, Eastell R et al.; HORIZON Pivotal Fracture Trial. Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med 2007; 356: 1809-22.
    • (2007) N Engl J Med , vol.356 , pp. 1809-1822
    • Black, D.M.1    Delmas, P.D.2    Eastell, R.3
  • 8
    • 77957657154 scopus 로고    scopus 로고
    • Atypical fractures as a potential complication of long-term bisphosphonate therapy
    • Sellmeyer DE. Atypical fractures as a potential complication of long-term bisphosphonate therapy. JAMA 2010; 304: 1480-4.
    • (2010) JAMA , vol.304 , pp. 1480-1484
    • Sellmeyer, D.E.1
  • 9
    • 67650468390 scopus 로고    scopus 로고
    • Association of low-energy femoral fractures with prolonged bisphosphonate use: a case control study
    • Lenart BA, Neviaser AS, Lyman S et al. Association of low-energy femoral fractures with prolonged bisphosphonate use: a case control study. Osteoporos Int 2009; 20: 1353-62.
    • (2009) Osteoporos Int , vol.20 , pp. 1353-1362
    • Lenart, B.A.1    Neviaser, A.S.2    Lyman, S.3
  • 10
    • 78650038476 scopus 로고    scopus 로고
    • Cumulative alendronate dose and the long-term absolute risk of subtrochanteric and diaphyseal femur fractures: a register-based national cohort analysis
    • Abrahamsen B, Eiken P, Eastell R. Cumulative alendronate dose and the long-term absolute risk of subtrochanteric and diaphyseal femur fractures: a register-based national cohort analysis. J Clin Endocrinol Metab 2010; 95: 5258-65.
    • (2010) J Clin Endocrinol Metab , vol.95 , pp. 5258-5265
    • Abrahamsen, B.1    Eiken, P.2    Eastell, R.3
  • 11
    • 79955722153 scopus 로고    scopus 로고
    • Bisphosphonate use and atypical fractures of the femoral shaft
    • Schilcher J, Michaëlsson K, Aspenberg P. Bisphosphonate use and atypical fractures of the femoral shaft. N Engl J Med 2011; 364: 1728-37.
    • (2011) N Engl J Med , vol.364 , pp. 1728-1737
    • Schilcher, J.1    Michaëlsson, K.2    Aspenberg, P.3
  • 12
    • 79951974391 scopus 로고    scopus 로고
    • Bisphosphonate use and the risk of subtrochanteric or femoral shaft fractures in older women
    • Park-Wyllie LY, Mamdani MM, Juurlink DN et al. Bisphosphonate use and the risk of subtrochanteric or femoral shaft fractures in older women. JAMA 2011; 305: 783-9.
    • (2011) JAMA , vol.305 , pp. 783-789
    • Park-Wyllie, L.Y.1    Mamdani, M.M.2    Juurlink, D.N.3
  • 13
    • 77952314262 scopus 로고    scopus 로고
    • Bisphosphonates and fractures of the subtrochanteric or diaphyseal femur
    • Black DM, Kelly MP, Genant HK et al.; Fracture Intervention Trial Steering Committee; HORIZON Pivotal Fracture Trial Steering Committee. Bisphosphonates and fractures of the subtrochanteric or diaphyseal femur. N Engl J Med 2010; 362: 1761-71.
    • (2010) N Engl J Med , vol.362 , pp. 1761-1771
    • Black, D.M.1    Kelly, M.P.2    Genant, H.K.3
  • 14
    • 77949778981 scopus 로고    scopus 로고
    • AHRQ Publication No. 10(14)-EHC063-EF. Rockville, MD: Agency for Healthcare Research and Quality
    • Methods Guide for Effectiveness and Comparative Effectiveness Reviews. AHRQ Publication No. 10(14)-EHC063-EF. Rockville, MD: Agency for Healthcare Research and Quality, 2014
    • (2014) Methods Guide for Effectiveness and Comparative Effectiveness Reviews
  • 15
    • 34547851792 scopus 로고    scopus 로고
    • Tools for assessing quality and susceptibility to bias in observational studies in epidemiology: a systematic review and annotated bibliography
    • Sanderson S, Tatt ID, Higgins JP. Tools for assessing quality and susceptibility to bias in observational studies in epidemiology: a systematic review and annotated bibliography. Int J Epidemiol 2007; 36: 666-76.
    • (2007) Int J Epidemiol , vol.36 , pp. 666-676
    • Sanderson, S.1    Tatt, I.D.2    Higgins, J.P.3
  • 16
    • 0035318124 scopus 로고    scopus 로고
    • Methods Work Group, Third US Preventive Services Task Force. Current methods of the US Preventive Services Task Force: a review of the process
    • Harris RP, Helfand M, Woolf SH et al.; Methods Work Group, Third US Preventive Services Task Force. Current methods of the US Preventive Services Task Force: a review of the process. Am J Prev Med 2001; 20(3 suppl): 21-35.
    • (2001) Am J Prev Med , vol.20 , Issue.3 , pp. 21-35
    • Harris, R.P.1    Helfand, M.2    Woolf, S.H.3
  • 18
    • 0030922816 scopus 로고    scopus 로고
    • Bias in meta-analysis detected by a simple, graphical test
    • Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ 1997; 315: 629-34.
    • (1997) BMJ , vol.315 , pp. 629-634
    • Egger, M.1    Davey Smith, G.2    Schneider, M.3    Minder, C.4
  • 19
    • 84859001212 scopus 로고    scopus 로고
    • The Cochrane Collaboration's tool for assessing risk of bias in randomised trials
    • Higgins JP, Altman DG, Gøtzsche PC et al.; Cochrane Bias Methods Group; Cochrane Statistical Methods Group. The Cochrane Collaboration's tool for assessing risk of bias in randomised trials. BMJ 2011; 343: d5928.
    • (2011) BMJ , vol.343 , pp. d5928
    • Higgins, J.P.1    Altman, D.G.2    Gøtzsche, P.C.3
  • 20
    • 79951680455 scopus 로고    scopus 로고
    • Risk of femoral shaft and subtrochanteric fractures among users of bisphosphonates and raloxifene
    • Vestergaard P, Schwartz F, Rejnmark L, Mosekilde L. Risk of femoral shaft and subtrochanteric fractures among users of bisphosphonates and raloxifene. Osteoporos Int 2011; 22: 993-1001.
    • (2011) Osteoporos Int , vol.22 , pp. 993-1001
    • Vestergaard, P.1    Schwartz, F.2    Rejnmark, L.3    Mosekilde, L.4
  • 21
    • 66349094278 scopus 로고    scopus 로고
    • Subtrochanteric and diaphyseal femur fractures in patients treated with alendronate: a register-based national cohort study
    • Abrahamsen B, Eiken P, Eastell R. Subtrochanteric and diaphyseal femur fractures in patients treated with alendronate: a register-based national cohort study. J Bone Miner Res 2009; 24: 1095-102.
    • (2009) J Bone Miner Res , vol.24 , pp. 1095-1102
    • Abrahamsen, B.1    Eiken, P.2    Eastell, R.3
  • 22
    • 84873696824 scopus 로고    scopus 로고
    • Risk factors for subtrochanteric and diaphyseal fractures: the study of osteoporotic fractures
    • Napoli N, Schwartz AV, Palermo L et al. Risk factors for subtrochanteric and diaphyseal fractures: the study of osteoporotic fractures. J Clin Endocrinol Metab 2013; 98: 659-67.
    • (2013) J Clin Endocrinol Metab , vol.98 , pp. 659-667
    • Napoli, N.1    Schwartz, A.V.2    Palermo, L.3
  • 23
    • 84862988633 scopus 로고    scopus 로고
    • Increasing occurrence of atypical femoral fractures associated with bisphosphonate use
    • Meier RP, Perneger TV, Stern R, Rizzoli R, Peter RE. Increasing occurrence of atypical femoral fractures associated with bisphosphonate use. Arch Intern Med 2012; 172: 930-6.
    • (2012) Arch Intern Med , vol.172 , pp. 930-936
    • Meier, R.P.1    Perneger, T.V.2    Stern, R.3    Rizzoli, R.4    Peter, R.E.5
  • 24
    • 82855166071 scopus 로고    scopus 로고
    • Hip and subtrochanteric or diaphyseal femoral fractures in alendronate users: a 10-year, nationwide retrospective cohort study in Taiwanese women
    • Hsiao FY, Huang WF, Chen YM et al. Hip and subtrochanteric or diaphyseal femoral fractures in alendronate users: a 10-year, nationwide retrospective cohort study in Taiwanese women. Clin Ther 2011; 33: 1659-67.
    • (2011) Clin Ther , vol.33 , pp. 1659-1667
    • Hsiao, F.Y.1    Huang, W.F.2    Chen, Y.M.3
  • 25
    • 84873453239 scopus 로고    scopus 로고
    • Oral bisphosphonates are associated with increased risk of subtrochanteric and diaphyseal fractures in elderly women: a nested case-control study
    • Erviti J, Alonso A, Oliva B et al. Oral bisphosphonates are associated with increased risk of subtrochanteric and diaphyseal fractures in elderly women: a nested case-control study. BMJ Open 2013;3: e002091.
    • (2013) BMJ Open , vol.3 , pp. e002091
    • Erviti, J.1    Alonso, A.2    Oliva, B.3
  • 26
    • 84891034178 scopus 로고    scopus 로고
    • Atypical subtrochanteric and diaphyseal femoral fractures: second report of a task force of the American Society for Bone and Mineral Research
    • October 1 [Epub ahead of print]
    • Shane E, Burr D, Abrahamsen B et al. Atypical subtrochanteric and diaphyseal femoral fractures: second report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res 2013 October 1 [Epub ahead of print] doi:10.1002/jbmr.1998.
    • (2013) J Bone Miner Res
    • Shane, E.1    Burr, D.2    Abrahamsen, B.3
  • 27
    • 15944413442 scopus 로고    scopus 로고
    • Severely suppressed bone turnover: a potential complication of alendronate therapy
    • Odvina CV, Zerwekh JE, Rao DS et al. Severely suppressed bone turnover: a potential complication of alendronate therapy. J Clin Endocrinol Metab 2005; 90: 1294-301.
    • (2005) J Clin Endocrinol Metab , vol.90 , pp. 1294-1301
    • Odvina, C.V.1    Zerwekh, J.E.2    Rao, D.S.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.